What proportion of breast cancers are progesterone receptor (PR) positive?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 12, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Progesterone Receptor Positivity in Breast Cancer

Approximately 55-65% of breast cancers are progesterone receptor (PR) positive, though this varies significantly based on assay sensitivity, patient age, and whether the tumor is also estrogen receptor positive.

Key Epidemiological Data

The proportion of PR-positive breast cancers depends on several factors:

Overall Prevalence

  • 57.4% of breast tumors demonstrate PR positivity by immunohistochemistry in large contemporary analyses 1
  • Historical data using standardized IHC assays with a 10% threshold showed 51-63% PR positivity, with higher rates (63%) in laboratories using high-sensitivity assays 2

Critical Variables Affecting PR Positivity Rates

Assay Sensitivity: This is the most important technical factor. Laboratories with high-sensitivity IHC assays detect PR positivity in 63% of cases, while those with low-sensitivity assays detect only 51% (p = 0.022) 2. This 12% difference underscores why adherence to standardized protocols matters clinically.

Patient Age: PR positivity peaks in the 41-50 year age range, with lower rates in younger and older patients 2. This differs from ER, which shows highest positivity rates in patients >65 years.

ER Status Context: PR testing is used primarily for prognostic purposes in ER-positive cancers 3. The majority of PR-positive tumors are also ER-positive, making the ER+/PR+ phenotype the most common hormone receptor pattern.

Clinical Interpretation Framework

According to the 2020 ASCO/CAP guidelines 3:

  • PR-positive: ≥1% of tumor nuclei staining positive
  • PR-negative: <1% or 0% of tumor nuclei staining positive
  • Unlike ER, there is no "low positive" reporting category for PR

Important Caveats

The 79-84% figure often cited refers to ER positivity, not PR positivity 3. This is a common source of confusion. ER-positive rates have increased over time due to improved assay sensitivity and detection methods, but PR positivity remains lower at approximately 55-65%.

PR loss is clinically significant: Even in ER-positive tumors, PR negativity (the ER+/PR- phenotype) is associated with endocrine resistance and poorer prognosis 4, 5. This makes accurate PR testing essential for treatment planning, not just prognostication.

Quality control matters: The wide variation in reported PR positivity rates (51-63%) based on assay sensitivity 2 emphasizes the need for laboratories to use validated, high-sensitivity protocols and participate in external quality assessment programs.

References

Related Questions

How is the Allred scoring system calculated and interpreted for estrogen‑receptor or progesterone‑receptor staining in breast cancer?
Do patients gain weight when taking oral progesterone 100 mg in the evening combined with a transdermal estrogen patch?
How should I plan pregnancy with early-stage estrogen‑receptor‑positive and progesterone‑receptor‑positive breast cancer?
What endocrine therapy regimens are recommended for estrogen‑receptor or progesterone‑receptor positive breast cancer in pre‑menopausal, post‑menopausal, and metastatic settings?
What does an estrogen receptor (ER) Allred score of 4 out of 8 indicate?
What is the likely diagnosis for an 18‑month‑old child with a chronic draining sinus on the occipital scalp that initially produced white discharge now yellow, present for a year, and a swollen posterior cervical lymph node?
How should I manage recurrent rapid atrial fibrillation and palpitations after a binge drinking episode in a patient already taking amiodarone with a controlled ventricular rate?
How long should hemostasis and complete epithelialization be expected for an open wound in a healthy adult?
What is known about periurethral (Skene's) gland ejaculation, commonly referred to as squirting?
Is it safe to initiate progesterone therapy in a 51-year-old woman with severe menopausal symptoms who had a breast ultrasound and mammogram 14 months ago?
In a patient with amyotrophic lateral sclerosis who can still swallow but has dyspnea when speaking, what is the appropriate management?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.